title: [Drug induced angioedema (ACE-inhibitors and other)].
abstract: Angiotensin Converting Enzyme inhibitors (ACE-I) use is a frequent cause of AE and must be suspected systematically in all patients with AE. The risk of AE is increased in: black people, transplanted patients, those who take gliptins or immunosuppressants (mTOR i). Angiotensin converting enzyme inhibitors induced angioedema (ACE-I AE) can occur a few days to several years after the beginning of this treatment and persist a few months after stopping it. ACE-I AE affect mainly the face and particularly the tongue but also the abdomen. ACE-I AE can be life threatening, due to the involvement of the tongue and the larynx. ACE-I AE must be treated as in the hereditary form when life threatening signs are present, with icatibant or C1 inhibitor concentrate. AE can occur in 10% of angiotensin receptor blockers (ARBs) treated patients who had developed ACE-I AE.
authors.affiliation: AP-HP, DHU i2B, université Paris 6, hôpital Saint-Antoine, centre de références des angiœdèmes à kinines (CREAK), service de médecine interne, 75012 Paris, France. Electronic address: olivier.fain@sat.aphp.fr.
authors.forename: Olivier
authors.initials: O
authors.lastname: Fain
authors.affiliation: AP-HP, DHU i2B, université Paris 6, hôpital Saint-Antoine, centre de références des angiœdèmes à kinines (CREAK), service de médecine interne, 75012 Paris, France.
authors.forename: Arsène
authors.initials: A
authors.lastname: Mekinian
authors.affiliation: AP-HP, DHU i2B, université Paris 6, hôpital Saint-Antoine, centre de références des angiœdèmes à kinines (CREAK), service de médecine interne, 75012 Paris, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Gobert
authors.affiliation: AP-HP, DHU i2B, université Paris 6, hôpital Saint-Antoine, centre de références des angiœdèmes à kinines (CREAK), service de médecine interne, 75012 Paris, France.
authors.forename: Cam-Anh
authors.initials: CA
authors.lastname: Khau
authors.affiliation: AP-HP, université Paris 7, urgences, hôpital Louis-Mounier, 92700 Colombes, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Javaud
mesh_terms: D000799:Angioedema / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001920:Bradykinin / Q000009:adverse effects; D000075202:Contraindications; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005343:Fibrinolytic Agents; D007166:Immunosuppressive Agents; D001920:Bradykinin